HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
Dermatology Drug Development

Dermatology Drug Development is a dynamic and innovative field focused on discovering, developing, and bringing new medications to market for the treatment of various skin diseases and conditions. It encompasses a wide range of therapeutic areas, including inflammatory skin disorders like psoriasis, eczema, and acne, as well as skin cancers, infections, and genetic disorders. The process of dermatology drug development typically begins with basic research to identify potential drug targets and mechanisms underlying skin diseases. This is followed by preclinical studies to assess the safety and efficacy of candidate compounds using cell cultures and animal models. Clinical trials are then conducted to evaluate the safety, efficacy, and tolerability of investigational drugs in human subjects. These trials are conducted in multiple phases, including Phase I trials to assess safety, Phase II trials to evaluate efficacy and dose-ranging, and Phase III trials to confirm efficacy and monitor adverse effects in larger patient populations. Regulatory approval from health authorities such as the FDA or EMA is required before a new dermatology drug can be marketed and made available to patients. This process involves submitting comprehensive data from preclinical and clinical studies demonstrating the drug's safety and efficacy. Once approved, dermatology drugs may undergo post-marketing surveillance to monitor for long-term safety and efficacy in real-world settings. Ongoing research and development efforts continue to refine existing treatments and explore new therapeutic approaches, including targeted therapies, biologics, gene therapies, and nanotechnology-based delivery systems. Collaboration between pharmaceutical companies, academic institutions, dermatologists, and regulatory agencies is essential for advancing dermatology drug development and improving patient care. By addressing unmet medical needs and harnessing scientific advances, dermatology drug development plays a crucial role in promoting skin health and enhancing quality of life for patients worldwide.

Committee Members
Speaker at Dermatology and Cosmetology 2025 - Sergei A Grando

Sergei A Grando

University of California Irvine, United States
Speaker at Dermatology and Cosmetology 2025 - Gustavo Hector Leibaschoff

Gustavo Hector Leibaschoff

World Society of Cosmetic Gynecology, United States
Speaker at Dermatology and Cosmetology 2025 - Nalini Kaul

Nalini Kaul

Princeton Consumer Research, Canada
Speaker at Dermatology and Cosmetology 2025 - Dechelette Corinne

Dechelette Corinne

La Peau Autrement, France
IDC 2025 Speakers
Speaker at Dermatology and Cosmetology 2025 - Rachita Dhurat

Rachita Dhurat

LTMMC & LTMG Hospital, India
Speaker at Dermatology and Cosmetology 2025 - Frederick H Silver

Frederick H Silver

Robert Wood Johnson Medical School, Rutgers University, United States
Speaker at Dermatology and Cosmetology 2025 - Daan Thorn Leeson

Daan Thorn Leeson

Rodan + Fields, United States
Speaker at Dermatology and Cosmetology 2025 - Brannon Claytor

Brannon Claytor

Claytor Noone Plastic Surgery, United States
Speaker at Dermatology and Cosmetology 2025 - Katie L Frederickson

Katie L Frederickson

Meharry Medical College, United States
Speaker at Dermatology and Cosmetology 2025 - Xiaozhun Hang

Xiaozhun Hang

Queensland Institute of Medical Research Berghofer, Australia
Tags

Submit your abstract Today

Watsapp